| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA3087175
Max Phase: Preclinical
Molecular Formula: C16H14N2O3
Molecular Weight: 282.30
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: COc1nn(Cc2cccc(-c3ccccc3)c2)c(=O)o1
Standard InChI: InChI=1S/C16H14N2O3/c1-20-15-17-18(16(19)21-15)11-12-6-5-9-14(10-12)13-7-3-2-4-8-13/h2-10H,11H2,1H3
Standard InChI Key: MYLOLXFKMORPMN-UHFFFAOYSA-N
Associated Targets(Human)
Monoacylglycerol lipase ABHD12 195 Activities
Monoacylglycerol lipase ABHD6 331 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Monoglyceride lipase 1909 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Anandamide amidohydrolase 3465 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 282.30 | Molecular Weight (Monoisotopic): 282.1004 | AlogP: 2.56 | #Rotatable Bonds: 4 |
| Polar Surface Area: 57.26 | Molecular Species: | HBA: 5 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.99 | CX LogD: 3.99 |
| Aromatic Rings: 3 | Heavy Atoms: 21 | QED Weighted: 0.74 | Np Likeness Score: -1.11 |
References
| 1. Patel JZ, Parkkari T, Laitinen T, Kaczor AA, Saario SM, Savinainen JR, Navia-Paldanius D, Cipriano M, Leppänen J, Koshevoy IO, Poso A, Fowler CJ, Laitinen JT, Nevalainen T.. (2013) Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors., 56 (21): [PMID:24083878] [10.1021/jm400923s] |
| 2. Patel JZ, van Bruchem J, Laitinen T, Kaczor AA, Navia-Paldanius D, Parkkari T, Savinainen JR, Laitinen JT, Nevalainen TJ.. (2015) Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors., 23 (19): [PMID:26344596] [10.1016/j.bmc.2015.08.030] |
Source
Source(1):